On Invalid Date, Unicycive Therapeutics (NASDAQ: UNCY) reported Q1 2023 earnings per share (EPS) of -$0.97, up 304.17% year over year. Total Unicycive Therapeutics earnings for the quarter were -$14.77 million. In the same quarter last year, Unicycive Therapeutics's earnings per share (EPS) was -$0.24.
As of Q2 2023, Unicycive Therapeutics's earnings has grown year over year. Unicycive Therapeutics's earnings in the past year totalled -$29.29 million.
What was UNCY's revenue last quarter?
On Invalid Date, Unicycive Therapeutics (NASDAQ: UNCY) reported Q1 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Unicycive Therapeutics's revenue was $0.00.
What was UNCY's revenue growth in the past year?
As of Q2 2023, Unicycive Therapeutics's revenue has grown null year over year. Unicycive Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.